• For Institutions

  • Download
  • Help
  • About

longbridgelongbridge
longbridgelongbridge
Products
Pricing
Markets
Global Markets
Stock Screener
Information
Insights
News
Live
Academy
Affiliate Program
Promotions
PortAI
EN
English
简体中文
繁體中文
繁體中文(廣東話)Posts & comments will be shown in Cantonese
Search...
Quote ListQuote List
Overview
News
Financials
© 2025 Longbridge|Disclaimer

Event Tracking

Dec8
Agios Pharmaceuticals' Pyrukynd Expected to Receive FDA Approval
17:42
Nov19
H.C. Wainwright Analyst Reiterates Buy Rating on Agios Pharma and Sets Target Price
17:54
Agios Announces Topline Results of Mitapivat Phase 3 Trial in Sickle Cell Disease
12:26
Nov13
Agios Pharmaceuticals' Chief Medical Officer Reports Common Stock Disposition
21:10
Oct30
Agios Pharmac released FY2025 Q3 earnings on October 30 Pre-Market EST, actual revenue USD 12.88 M (forecast USD 10.61 M), actual EPS USD -1.7799 (forecast USD -1.8961)
13:30
Agios Pharmaceuticals released FY2025 9 Months earnings on October 30 Pre-Market (EST), actual revenue USD 34.06 M, actual EPS USD -5.2675
13:30

Schedules & Filings

Schedules
Filings
Oct30
Earning Release(EST)

FY2025 Q3 Earning Release (USD) Revenue 12.88 M, Net Income -103.43 M, EPS -1.7799

Jul31
Earning Release(EST)

FY2025 Q2 Earning Release (USD) Revenue 12.46 M, Net Income -112.02 M, EPS -1.9336

May1
Earning Release(EST)

FY2025 Q1 Earning Release (USD) Revenue 8.726 M, Net Income -89.29 M, EPS -1.5539

View More

Stock List

Top Gainers
Top Decliners
China Concepts
Symbol
Price
%Chg
Change
MSOX
7.940
+107.85%
+4.120
YCBD
1.200
+90.17%
+0.569
THH
15.520
+57.72%
+5.680
WEED
25.325
+55.65%
+9.055
NCI
1.920
+54.84%
+0.680
CNBS
34.820
+54.57%
+12.293
MSOS
5.800
+54.26%
+2.040
CGC
1.740
+53.98%
+0.610
RYM
23.800
+47.73%
+7.690
TLRY
12.150
+44.13%
+3.720
View More